Nurix Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $2.90B
- P/E (TTM)
- 10.8
- Dividend yield
- 0.00%
About Nurix Therapeutics
Pharmaceutical Preparations, SIC 2834
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company that discovers and develops targeted protein degradation medicines for cancer and inflammatory diseases. Its clinical drug pipeline features bexobrutideg, a Bruton's tyrosine kinase degrader; zelebrudomide, a dual degrader of kinase and transcription factors; and NX-1607, a CBL-B inhibitor. The company also creates preclinical degraders and degrader antibody conjugates. Nurix aims to treat patients with unmet medical needs, while collaborating with biopharmaceutical companies, including Gilead Sciences, Sanofi, and Pfizer, to advance partnered discovery programs.
The company operates clinical studies across multiple regions, enrolling patients at trial sites in the United States, the United Kingdom, and selected European nations. Its collaborative agreements cover research and commercialization options in the United States, while the company retains global rights to its lead clinical assets. The provided text does not mention the location of Nurix's corporate headquarters.
Summary of the business section of Nurix Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Nurix Therapeutics, Inc.
- Founded
- 2012
- Headquarters
- Brisbane, CA
- Address
- 1600 Sierra Point Pkwy 94005
- Phone
- (415) 660-5320
- Website
- www.nurixtx.com
- Employees
- 317, Nov 30, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- November 30
- Auditor
- PricewaterhouseCoopers LLP, San Jose, California
Stock & identifiers
- Ticker
- NRIX
- Exchange
- Nasdaq
- IPO date
- Jul 24, 2020
- Shares outstanding
- 104M, Jun 30, 2026
- Public float
- $807.50M, May 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1549595
- CUSIP
- 67080M103
- ISIN
- US67080M1036
- EIN
- 27-0838048
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Arthur T. Sands | President, CEO, Director | 608,333 |
| Christine Ring | Chief Legal Officer | 9,510 |
| Gwenn Hansen | Chief Scientific Officer | 118,679 |
| Houte Hans van | Chief Financial Officer | 40,166 |
| Paul M. Silva | Director | – |
| Anil Kapur | Director | – |
| David L. Lacey | Director | 33,333 |
| Roger D. Dansey | Director | – |
| Edward C. Saltzman | Director | – |
| Roy D. Baynes | Director | – |
| Judith A. Reinsdorf | Director | – |
| Julia P. Gregory | Director | 10,750 |
| Lori Anne Kunkel | Director | 0 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Arthur T. Sands | $6.37M | -$1.07M | $2.35M | $61 | $126 |
| FY2024 Arthur T. Sands | $5.81M | $23.31M | $2.02M | $77 | $99 |
| FY2023 Arthur T. Sands | $4.36M | -$913.89K | $1.62M | $22 | $82 |
| FY2022 Arthur T. Sands | $9.42M | -$5.02M | $4.07M | $43 | $91 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of November 30, 2025, we had 317 full-time or part-time employees, of which approximately 38% have earned an M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 24, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 20, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
| Sep 18, 2015 | Name change | Name changed from Nurix, Inc. to Nurix Therapeutics, Inc. |